Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic RNA Polymerases00:58

Eukaryotic RNA Polymerases

27.4K
RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
All three eukaryotic RNAPs require specific transcription factors, of which the...
27.4K
Transcription Initiation01:47

Transcription Initiation

21.6K
Initiation is the first step of transcription in eukaryotes. Prokaryotic RNA Polymerase (RNAP) can bind to the template DNA and start transcribing. On the other hand, transcription in eukaryotes requires additional proteins, called transcription factors, to first bind to the promoter region in the DNA template. This binding helps recruit the specific RNAP that can assemble on the DNA and start transcription.
The promoters and enhancers and their accessory proteins allow tight regulation of...
21.6K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

9.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
9.8K
piRNA - Piwi-interacting RNAs02:57

piRNA - Piwi-interacting RNAs

7.7K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.7K
The Nucleolus02:55

The Nucleolus

10.5K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Photochemically-enabled, post-translational production of C-terminal amides.

Nature communications·2024
Same author

Unanticipated Characteristics of a Selective, Potent Neuromedin-U Receptor 2 Agonist.

ACS bio & med chem Au·2023
Same author

Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1.

RSC chemical biology·2022
Same author

Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles.

Organic & biomolecular chemistry·2021
Same author

A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors.

Analytical methods : advancing methods and applications·2020

Related Experiment Video

Updated: Feb 28, 2026

Visualization of DNA Repair Proteins Interaction by Immunofluorescence
07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

11.3K

Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.

Xiuxiu Lu1, Urszula Nowicka1, Vinidhra Sridharan1

  • 1Protein Processing Section, Structural Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, USA.

Nature Communications
|June 10, 2017
PubMed
Summary

The proteasome receptor hRpn13 (human Rad23 homologue) binds Uch37, a deubiquitinating enzyme. The cancer drug RA190 inactivates Uch37, preventing proteasome substrate degradation.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip
13:34

Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip

Published on: September 29, 2012

28.2K

Related Experiment Videos

Last Updated: Feb 28, 2026

Visualization of DNA Repair Proteins Interaction by Immunofluorescence
07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

11.3K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip
13:34

Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip

Published on: September 29, 2012

28.2K

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • The proteasome system degrades proteins, crucial for cellular regulation.
  • hRpn13 (human Rad23 homologue) is a proteasome receptor that binds and activates Uch37 (UCHL5), a deubiquitinating enzyme.
  • RA190 is a bis-benzylidine piperidone compound that restricts cancer growth.

Purpose of the Study:

  • To elucidate the structural basis of hRpn13-hRpn2 interaction.
  • To understand the mechanism of RA190 action on hRpn13 and Uch37.
  • To investigate the role of hRpn13 in RA190-mediated cancer therapy.

Main Methods:

  • X-ray crystallography to determine the structure of hRpn13 bound to hRpn2.
  • Biophysical analyses (e.g., SPR, ITC) to quantify binding affinities.
  • Cell-based assays (e.g., Western blotting, gene deletion) to assess functional consequences.

Main Results:

  • The structure reveals hRpn2 binding to the hRpn13 Pru domain, with an hRpn2 extension blocking the RA190-binding site.
  • hRpn13 shows preferential binding to hRpn2 and proteasomes over RA190.
  • RA190 directly binds and inactivates Uch37, independent of hRpn13.
  • hRpn13 deletion abolishes RA190-induced proteasome substrate accumulation.

Conclusions:

  • RA190 targets hRpn13 and Uch37 via parallel mechanisms.
  • At the proteasome, RA190-inactivated Uch37 cannot remove ubiquitin chains from hRpn13-bound substrates.
  • This study provides insights into the mechanism of RA190 as a potential cancer therapeutic.